Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 5/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869751 | 0.79 | CA1 (0.41) | CA1CA2CA9 | |
| SCHEMBL14869856 | 0.78 | CA1 (0.41) | CA1CA2CA9 | |
| SCHEMBL14869708 | 0.77 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL15100688 | 0.74 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL21984217 | 0.72 | ADORA2A (0.39) | CA1CA2CA9 | |
| SCHEMBL14869757 | 0.71 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL20799826 | 0.70 | CA1 (0.40) | CA1CA2CA9 | |
| SCHEMBL14869795 | 0.69 | CA1 (0.45) | CA1CA2CA9ESR1ESR2 | |
| SCHEMBL14869650 | 0.69 | CA1 (0.37) | CA1CA2CA9 | |
| SCHEMBL19165407 | 0.69 | CA1 (0.31) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.